Skip to content

Psilocybin for anxiety: all studies

Page 11 of 31: studies 101 to 110 of 308, newest first. Back to the psilocybin for anxiety overview

Research

MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More

Psychiatric News April 23, 2024 Terri D’arrigo

announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder....

Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review

Journal For International Medical Graduates April 18, 2024 Sarosh Nawaz, Abdulaziz Mohammed Althwanay, B Esraa M. Aledani Mb Ch et al.

The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine...

Acute Adverse Effects of Therapeutic Doses of Psilocybin

JAMA Network Open April 10, 2024 Akhila Yerubandi, Catherine Harrington, Joshua Caballero et al. 80 citations

Importance Psilocybin has been studied in the treatment of depression and anxiety disorders. Clinical studies have mainly focused on efficacy, with systematic reviews showing favorable efficacy; however, none have primarily focused on psilocybin safety. Objective To evaluate the acute adverse effects of psilocybin at therapeutic doses in the treatment of depression and anxiety. Data Sources...

Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor

iScience April 9, 2024 Ram Harari, Ipsita Chatterjee, Dmitriy Getselter et al. 20 citations

Psilocybin, and its metabolite psilocin, induces psychedelic effects through activation of the 5-HT2A receptor. Psilocybin has been proposed as a treatment for depression and anxiety but sometimes induces anxiety in humans. An understanding of mechanisms underlying the anxiety response will help to better develop therapeutic prospects of psychedelics. In the current study, psilocybin induced an...

Psilocybin with Acceptance and Commitment Therapy (ACT) for the Treatment of Social Anxiety Disorder (SAD)

March 1, 2024 Aspen Allred, Aspen Allred

Social Anxiety Disorder (SAD) is a debilitating mental health condition characterized by an overwhelming fear and anxiety of social rejection that can lead to chronic patterns of social behavioral avoidance. Despite the existence of traditional efficacious treatments, a significant number of individuals either do not respond to treatment or experience a recurrence of symptoms over extended...

DOI: 10.15760/honors.1468 (opens in new tab) Full text (opens in new tab) Psilocybin Biopsychosocial model Social anxiety Psychotherapist +3

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

Current Psychiatry Research and Reviews January 21, 2024 Payal Ghosh, Debjeet Sur 1 citation

: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic...

Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.

Behavioral Neuroscience January 18, 2024 Zahra Ghofrani-Jahromi, Sarah Nouri-Darehno, Mehrsa Rahimi-Danesh et al. 22 citations

Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on...

Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma

Cancer Research January 16, 2024 Kelsey Klute, Lou Lukas, Soonjo Hwang et al. 2 citations

Abstract Background: Psychological distress is a common reaction to a cancer diagnosis and its treatment. Distress impacts quality of life, adherence to treatment, decision making and survival. Patients with pancreatic adenocarcinoma (PDAC) experience exceptionally high rates of psychological distress, most commonly depression, anxiety and suicidality. Psilocybin, a serotonergic psychedelic...

EFEITOS PSICOLÓGICOS DA PSILOCIBINA EM PORTADORES DE CÂNCER TERMINAL: Uma revisão de escopo

Psicologia e Saúde em Debate January 10, 2024 Leonardo Hercílio Florêncio Silva, Júnia Aparecida Laia Da Mata, Sabrina Stefanello et al.

Psilocybin is a natural substance with hallucinogenic properties that has recently been used in the field of health. It is an alkaloid that, when associated with psychotherapy, has shown benefits in the treatment of depression and anxiety. This study aims to analyze the current state of knowledge about the psychological effects of psilocybin in patients with terminal cancer. The method used was...